Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
53 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Keloids - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keloids - Pipeline Review, H2 2016, provides an overview of the Keloids (Keloids) pipeline landscape. Keloids are a growth of extra scar tissue where the skin has healed after an injury. Symptoms include flesh-colored, red, or pink, lumpy (nodular) or ridged, irritated from friction such as rubbing on clothing and tender and itchy. Risk factors include age and family history. Treatment includes corticosteroid, radiation, surgical removal and silicone gel or patches. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keloids - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Keloids (Keloids), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Keloids (Keloids) pipeline guide also reviews of key players involved in therapeutic development for Keloids and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 4 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively. Keloids (Keloids) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Keloids (Keloids). - The pipeline guide reviews pipeline therapeutics for Keloids (Keloids) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Keloids (Keloids) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Keloids (Keloids) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Keloids (Keloids) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Keloids (Keloids). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Keloids (Keloids) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Keloids Overview 6 Therapeutics Development 7 Pipeline Products for Keloids - Overview 7 Pipeline Products for Keloids - Comparative Analysis 8 Keloids - Therapeutics under Development by Companies 9 Keloids - Therapeutics under Investigation by Universities/Institutes 10 Keloids - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Keloids - Products under Development by Companies 13 Keloids - Products under Investigation by Universities/Institutes 14 Keloids - Companies Involved in Therapeutics Development 15 FirstString Research Inc 15 RXi Pharmaceuticals Corp 16 Topadur Pharma AG 17 Tumorend LLC 18 viDA Therapeutics Inc 19 Yuhan Corp 20 Keloids - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Target 22 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 30 CM-101 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Granexin - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 koebnerisin - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 psoriasin - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 RXI-109 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 TOPN-44 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 V-2248 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 VTI-3000 Series - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 YH-siRNA1 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 Keloids - Dormant Projects 45 Keloids - Discontinued Products 46 Keloids - Product Development Milestones 47 Featured News & Press Releases 47 Jun 02, 2015: RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 47 Apr 29, 2014: RXi Pharmaceuticals Announces Initiation of Phase 2a Keloid Study 47 Mar 05, 2014: RXi Pharmaceuticals Granted Key Patent Related to Self-Delivering Technology for the Treatment of Fibrotic Disorders 48 Dec 04, 2013: RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period 48 Nov 18, 2013: RXi Pharmaceuticals and Ethicor Announce the Signing of a Distribution Agreement for RXI-109 in the European Union under the "Specials" Provision 49 Jun 06, 2013: RXi Pharmaceuticals Announces Positive Results In First Double Blind Study In Healthy Volunteers With RXI-109 49 Jan 30, 2013: RXi Pharma Completes Enrollment In Second Phase I Trial For RXI-109 Program 50 Appendix 52 Methodology 52 Coverage 52 Secondary Research 52 Primary Research 52 Expert Panel Validation 52 Contact Us 52 Disclaimer 53
List of Tables
Number of Products under Development for Keloids, H2 2016 7 Number of Products under Development for Keloids - Comparative Analysis, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Number of Products under Investigation by Universities/Institutes, H2 2016 10 Comparative Analysis by Clinical Stage Development, H2 2016 11 Comparative Analysis by Early Stage Development, H2 2016 12 Products under Development by Companies, H2 2016 13 Products under Investigation by Universities/Institutes, H2 2016 14 Keloids - Pipeline by FirstString Research Inc, H2 2016 15 Keloids - Pipeline by RXi Pharmaceuticals Corp, H2 2016 16 Keloids - Pipeline by Topadur Pharma AG, H2 2016 17 Keloids - Pipeline by Tumorend LLC, H2 2016 18 Keloids - Pipeline by viDA Therapeutics Inc, H2 2016 19 Keloids - Pipeline by Yuhan Corp, H2 2016 20 Assessment by Monotherapy Products, H2 2016 21 Number of Products by Stage and Target, H2 2016 23 Number of Products by Stage and Mechanism of Action, H2 2016 25 Number of Products by Stage and Route of Administration, H2 2016 27 Number of Products by Stage and Molecule Type, H2 2016 29 Keloids - Dormant Projects, H2 2016 45 Keloids - Discontinued Products, H2 2016 46
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.